BioCryst Pharmaceuticals Inc. (BCRX)

3.39
NASDAQ : Health Technology
Prev Close 3.48
Day Low/High 3.38 / 3.52
52 Wk Low/High 2.80 / 9.95
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 383.89M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Heavy Early Morning Activity On Biocryst Pharmaceuticals (BCRX)

Heavy Early Morning Activity On Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a pre-market mover with heavy volume candidate

Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)

Strong On High Relative Volume: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

BioCryst Pharmaceuticals is Now Oversold (BCRX)

BioCryst Pharmaceuticals is Now Oversold (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

Setting Up for Renewed Strength

Higher lows between now and Labor Day should confirm the end of the correction.

Will This Coverage Initiation Help BioCryst Pharmaceuticals (BCRX) Stock Today?

Will This Coverage Initiation Help BioCryst Pharmaceuticals (BCRX) Stock Today?

J.P. Morgan initiated coverage on BioCryst Pharmaceuticals (BCRX) with an "overweight" rating and a $20 price target for year-end 2015.

Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal Stock

Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

'Fast Money' Recap: Is Michael Kors Still in Fashion?

'Fast Money' Recap: Is Michael Kors Still in Fashion?

The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.

A Decent First Step

Does today's bounce means this little correction is ending?

Arista Networks and GoPro Are Among This Week's 4 Breakout Stocks to Watch

Arista Networks and GoPro Are Among This Week's 4 Breakout Stocks to Watch

bioCryst Pharmaceuticals and Arris Enterprises also appear to have more room to run.

3 Biotech Stocks Breaking Out on Big Volume

3 Biotech Stocks Breaking Out on Big Volume

These biotech stocks rising on unusual volume are within range of triggering breakout trades.

Short Interest In BioCryst Pharmaceuticals Moves 40% Higher

Short Interest In BioCryst Pharmaceuticals Moves 40% Higher

The most recent short interest data has been released by the NASDAQ for the 07/15/2014 settlement date, which shows a 2,252,345 share increase in total short interest for BioCryst Pharmaceuticals, Inc. , to 7,901,378, an increase of 39.87% since 06/30/2014.

Interesting BCRX Put And Call Options For March 2015

Interesting BCRX Put And Call Options For March 2015

Investors in BioCryst Pharmaceuticals, Inc. saw new options become available this week, for the March 2015 expiration.

'Fast Money' Recap: Fear Gauge Retreats but Be Cautious

'Fast Money' Recap: Fear Gauge Retreats but Be Cautious

The trading panel discussed Friday's rally and what they'll be buying and selling next week.

Biocryst Pharmaceuticals (BCRX) Is Today's Pre-Market Mover With Heavy Volume Stock

Biocryst Pharmaceuticals (BCRX) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a pre-market mover with heavy volume candidate

Why BioCryst Pharmaceuticals (BCRX) Stock Is Up Today

Why BioCryst Pharmaceuticals (BCRX) Stock Is Up Today

BioCryst Pharmaceuticals (BCRX) rose Tuesday after the company announced its experimental drug for treating a rare immune disorder was effective in decreasing the disease's attacks in a mid-stage trial.

TheStreet Quant Rating: D- (Sell)